S&P Futures
4,292.50 -5.75 (-0.13%) Dow Futures
33,860.00 -13.00 (-0.04%) Nasdaq Futures
13,660.75 -20.50 (-0.15%) Russell 2000 Futures
2,022.40 -1.40 (-0.07%) Crude Oil
88.75 -0.66 (-0.74%) Gold
1,795.80 -2.30 (-0.13%)
Celsion Corporation (CLSN)
After hours:
Chart Events
Performance Outlook
| Previous Close | 2.6000 |
| Open | 2.6200 |
| Bid | 0.0000 x 1000 |
| Ask | 0.0000 x 1400 |
| Day's Range | 2.5200 - 2.6387 |
| 52 Week Range | 1.8000 - 16.8000 |
| Volume | |
| Avg. Volume | 66,919 |
| Market Cap | 219.857M |
| Beta (5Y Monthly) | 2.29 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Celsion Corporation Reports Second Quarter 2022 Financial Results and Provides Business Update
DNA Mediated Immunotherapy and Next-Generation Vaccine Programs Supported with a Strong Balance Sheet Conference Call Begins Today at 11:00 a.m. EDT LAWRENCEVILLE, N.J., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage drug-development company focused on DNA-mediated immunotherapy and next-generation vaccines, today announced financial results for the three and six months ended June 30, 2022, and provided an update on its clinical development program of GEN-
- Reunion Neuroscience Inc. (Formerly Field Trip Health Ltd.) Reports Fiscal First Quarter 2023 Financial Results, Completed Corporate Reorganization on August 11, 2022GlobeNewswire
- Ascent Solar Completes Delivery of Another Major Contract and Announces Improved Second Quarter and First Six-Months Financial Results for 2022GlobeNewswire
- GlobeNewswire
Celsion Corporation to Hold Second Quarter 2022 Financial Results and Business Update Conference Call on Monday, August 15, 2022
LAWRENCEVILLE, N.J., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announced today that the Company will host a conference call at 11:00 a.m. ET on Monday, August 15, 2022 to discuss financial results for the second quarter ended June 30, 2022 and provide an update on product development programs with GEN-1, a DNA-based immunotherapy, currently in Phase II development for
- GlobeNewswire
Celsion Corporation Reports Inducement Grants under NASDQ Listing Rule 5646(c)(4)
LAWRENCEVILLE, N.J., July 19, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of (i) inducement stock options (the "Inducement Option Grants") to purchase a total of 177,000 shares of common stock, and (ii) restricted stock grants (the "Inducement Stock Grants") totaling 53,000 shares of commo
